[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"smoking-e-cigarette\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:smoking-e-cigarette":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":4},"100638763","smoking-cessation-with-wearables-to-improve-general-oral-health-and-quality-of-life-100638763",false,"NCT07593742","Smoking Cessation With Wearables to Improve General, Oral Health and Quality of Life","Smoking Cessation Programme in Telerehabilitation Assisted by Telemonitoring With Non-Invasive Wearable Devices for the Improvement of Oral Health, General Health and Quality of Life","Wear-Smile","Inclusion Criteria:\n\n* Subjects who smoke ≥ 5 cigarettes per day (traditional or equivalent in nicotine content in non-combustible tobacco or liquid\u002Fvape), regardless of the severity of nicotine dependence\n* Subjects ≥ 18 years of age\n* Ability and willingness to provide informed consent or presence of a legal representative who consents\n* Subjects in possession of home medical devices for measuring cardiopulmonary parameters (sphygmomanometer and pulse oximeter) (requirement applicable to participants assigned to the control group)\n\nExclusion Criteria:\n\n* Age \\\u003C 18\n* Pregnant or breastfeeding women\n* Subjects with a remote or current history of using smoking cessation methods\n* Subjects with acute dependence on alcohol or other substances of abuse other than nicotine\n* Pathologies with advanced neurocognitive degeneration\n* Unstable psychiatric conditions (subjects with active suicidal ideation, hospitalization for psychiatric reasons and\u002For changes in psychiatric medication for less than 3 months)\n* Inability or refusal to sign informed consent\n* Inability to access the integrated telemedicine platform and\u002For wearable remote monitoring devices (requirement applicable to participants assigned to the experimental group)","ALL","18 Years",{"count":20,"type":21},102,"ESTIMATED","INTERVENTIONAL",[24],"NA","Tobacco smoking remains one of the leading preventable causes of disease, disability, and premature death worldwide. According to the World Health Organization, tobacco use is responsible for more than eight million deaths each year globally, including deaths caused by direct smoking and exposure to secondhand smoke. Smoking is a major risk factor for a wide range of chronic diseases, including cardiovascular diseases, chronic respiratory diseases, several types of cancer, and numerous oral health conditions. In addition to systemic effects, tobacco use is strongly associated with oral potentially malignant disorders and oral squamous cell carcinoma, representing a significant burden for public health systems.\n\nDespite the well-documented health risks, smoking cessation remains difficult for many individuals due to the addictive properties of nicotine and the complex behavioral and psychological components associated with tobacco dependence. Multimodal smoking cessation programs that combine behavioral counseling, psychological support, and continuous monitoring have been shown to increase the likelihood of successful cessation. However, access to these programs may be limited by logistical barriers, including geographic distance, time constraints, and limited availability of specialized services.\n\nIn recent years, telemedicine and digital health technologies have emerged as promising tools to support healthcare delivery and improve access to treatment programs. Telemedicine platforms allow remote interaction between patients and healthcare professionals, facilitating communication, follow-up, and monitoring of patients over time. Additionally, wearable devices and remote monitoring systems enable the collection of physiological and behavioral data outside traditional clinical settings, providing clinicians with valuable information to support personalized interventions.\n\nThe aim of this study is to evaluate the effectiveness and feasibility of a smoking cessation program delivered through a telerehabilitation model supported by an integrated telemedicine platform and wearable remote monitoring devices. The program is designed to support individuals who smoke tobacco products, including both combustible tobacco and alternative nicotine-containing products, by providing behavioral and psychological interventions combined with continuous remote monitoring.\n\nParticipants enrolled in the study will be assigned to one of two groups. The intervention group will participate in a telerehabilitation program delivered through a dedicated telemedicine platform. This program will include structured behavioral and psychological treatment sessions aimed at supporting smoking cessation, along with remote monitoring through non-invasive wearable devices that allow healthcare professionals to track selected physiological parameters and patient engagement during the treatment process.\n\nThe control group will receive the same multimodal behavioral and psychological treatment program but delivered through conventional rehabilitation methods without the use of telemedicine technologies or wearable monitoring devices.\n\nBy comparing these two approaches, the study aims to explore whether the integration of telemedicine and wearable technologies into smoking cessation programs may improve patient engagement, facilitate monitoring, and potentially enhance the effectiveness of behavioral interventions aimed at reducing tobacco use. The findings of this study may contribute to the development of innovative digital health strategies for smoking cessation and provide evidence to support the integration of telemedicine into addiction treatment and preventive healthcare programs.",[27,28,29,30,31,32,33,34,35],"Smoking ( Cigarette)","Smoking (Tobacco) Addiction","Smoking Behaviors","Smoking Cessation","Smoking Dependence","Smoking Addiction","Smoking Cessation Intervention","Smoking E-cigarette","Smoking Abstinence",[37,38,39,40,41,42,43,44,45,46,47,48,49,50],"Smoking","Smoking cessation","Smoking addiction","Tobacco","Wearable device","Telerehabilitation","Oral Health","Periodontal Health","General Health","Quality of life","Periodontal disease","E-cigarette","Heat not burn tobacco","Smoking abstinence","NOT_YET_RECRUITING","2026-05-11",{"date":54,"type":55},"2026-05-18","ACTUAL",{"date":57,"type":21},"2026-06-01",{"date":59,"type":21},"2027-11-01",{"name":61,"class":62},"University of Salerno","OTHER",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100341150","phase-1-imaging-sex-differences-in-smoking-induced-pulmonary-inflammation-100341150","NCT03721822","Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation","Measurement of Pulmonary Inflammation Using 18F-NOS Positron Emission Tomography (PET\u002FCT) in E-cigarette Users","Inclusion Criteria:\n\n1. Participants will be 18-45 years of age\n2. Subject must meet one of the following criteria:\n\n   NIC vapers: current e-cigarette use of nicotine at least 5 days per week for the past year, no current combustible cigarette use, cannabis vaping, or cannabis smoking during the 30 days prior to study enrollment\n\n   CAN vapers: current e-cigarette use of cannabis at least 5 days per week for the past year, no current combustible cigarette use, cannabis smoking, or nicotine vaping during the 30 days prior to study enrollment\n\n   Cigarette smokers: current cigarette smoking of at least 5 cigarettes per day, 4 days per week for the past year with no e-cigarette use (cannabis or nicotine) during the 30 days prior to study enrollment\n\n   Dual combustible and e-cigarette users: current e-cigarette use of cannabis and\u002For nicotine at least 5 days per week for the past year with cigarette or cannabis smoking during the 30 day prior to study enrollment\n\n   Non-Smokers: reported non-smoking history or \\\u003C 100 lifetime cigarettes, \\\u003C 100 e-cigarette use episodes, and \\\u003C 100 lifetime cannabis use episodes\n3. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nExclusion Criteria:\n\n1. Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening and on scan day.\n2. Current untreated and unstable diagnosis of substance use disorder, except nicotine use disorder or cannabis use disorder\n3. Positive urine drug screen for opiates, methamphetamine or cocaine at screening\n4. Current unstable and\u002For untreated major depression or psychotic disorder per medical record review or self-reported\n5. Use of inhaled or oral corticosteroids or anti-inflammatory medications per medical record review or self-report\n6. History of lung trauma\n7. Active (or within the previous 4 weeks of screening) lung infection or lung disease that impact uptake of \\[18F\\]NOS (e.g. tuberculosis, cystic fibrosis)\n8. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n9. Any current or past medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study",true,"45 Years",{"count":73,"type":21},100,[75],"PHASE1","The purpose of this research is to measure the extent of lung inflammation between different groups of participants using a radioactive tracer called \\[18F\\]NOS. A radioactive tracer is a type of imaging drug that is labeled with a radioactive tag and injected into the body.",[78,34,79],"Smoking, Cigarette","Healthy Volunteer","RECRUITING","2025-09-29",{"date":83,"type":55},"2025-10-03",{"date":85,"type":55},"2018-10-23",{"date":87,"type":21},"2026-10-23",{"name":89,"class":62},"University of Pennsylvania",1]